Appointment Icon

UnityPoint Clinic - Express (Ankeny)

1055 Southwest Oralabor Road
Ankeny, IA 50023

Current Estimated Wait:
0 hr 9 min

UnityPoint Clinic - Express (Jordan Creek)

180 Jordan Creek Pkwy
West Des Moines, IA 50266

Current Estimated Wait:
0 hr 23 min

UnityPoint Clinic - Express (Waukee)

950 E Hickman Rd
Waukee, IA 50263

Current Estimated Wait:
0 hr 7 min

UnityPoint Clinic Behavioral Health Urgent Care - Des Moines

1250 East 9th Street
Des Moines, IA 50316

Current Estimated Wait:
0 hr 9 min

UnityPoint Clinic Urgent Care - Altoona

2720 8th Street Southwest
Altoona, IA 50009

Current Estimated Wait:
0 hr 56 min

UnityPoint Clinic Urgent Care - Ankeny Medical Park

3625 North Ankeny Boulevard
Ankeny, IA 50023

Current Estimated Wait:
1 hr 23 min

UnityPoint Clinic Urgent Care - Ingersoll

2103 Ingersoll Avenue
Des Moines, IA 50312

Current Estimated Wait:
0 hr 59 min

UnityPoint Clinic Urgent Care - Lakeview

6000 University Avenue
West Des Moines, IA 50266

Current Estimated Wait:
0 hr 30 min

UnityPoint Clinic Urgent Care - Southglen

6520 Southeast 14th Street
Des Moines, IA 50320

Current Estimated Wait:
2 hr 15 min

UnityPoint Clinic Urgent Care - Urbandale

5200 NW 100th Street
Urbandale, IA 50322

Current Estimated Wait:
0 hr 41 min

John Stoddard Cancer Center Continues to Lead the Way in Cancer Care

null

UnityPoint Health – John Stoddard Cancer Center (JSCC) continues to be a leader in advancing cancer care in Iowa. This year, radiation oncologists at Stoddard Cancer Center is the first in the state to offer Pluvicto apart from a clinical trial; and were the first in central Iowa to offer Lutathera. Both drugs are new infusion therapies to treat specific types of cancer.

“Infusion therapies using radio-pharmaceuticals are a relatively new area of advancement in cancer care,” said Sarah Zeidler, executive director of JSCC. “We’re appreciative of our clinical team and for the collaboration with team members across multiple departments that allows us to offer these new treatment options at John Stoddard Cancer Center.”

Pluvicto

Pluvicto, which was authorized for use by the Food and Drug Administration (FDA) in March 2022, is used to treat adults with an advanced case of prostate cancer that has spread to other parts of the body and has already been treated with other traditional cancer treatments. This infusion treatment delivers radiation to targeted cancer cells in the body causing the cells to die. The treatment takes about an hour and may be repeated every six weeks for up to six treatments.

“Prostate cancer is one of the leading causes of death for men in the United States,” said Arshin Sheybani, M.D. “We’re excited to be able to offer our patients this new treatment option and improve patient outcomes.”

The first Pluvicto treatment was given at Stoddard Cancer Center on July 22. Another patient is scheduled to receive the treatment later this month. Use of Pluvicto must be recommended by a doctor, and a specialized PET scan is used to determine if the individual is a candidate for the treatment.

Lutathera

Lutathera is a prescription medicine for adults with a certain type of cancer that affects the pancreas or gastrointestinal tract. It’s an infusion treatment that uses radiation to cause damage to cancer cells. The treatment takes about five hours and may be repeated every eight weeks for up to four treatments.

Lutathera received FDA approval in January 2018. Stoddard Cancer Center started using Lutathera earlier this year and has done 16 treatments to date.